ICNC Abstracts, ICNC 2018

Font Size: 
The electroclinical features of CHD2 mutation related epilepsy
Jiaoyang Chen, Jing Zhang, Qi Zeng, Liping Zhang, Hua Li, Zhixian Yang, Xiaoling Yang, Aijie Liu, Yuehua Zhang

Last modified: 2018-09-09

Abstract


Introduction: To summarize the electroclinical features of epilepsy associated with CHD2 mutations.

Methods: Patients with CHD2 mutations were collected. CHD2 mutations were identified by next-generation sequencing panels of epilepsy or whole exome sequencing.

Results: 17 patients with CHD2 mutations were enrolled. The onset age of seizure ranged from 3 months to 10 years and 5 months. Generalized tonic-clonic seizures (GTCS) were observed in 11 cases (11/17, 64.75%), and myoclonic seizures in 7 cases (7/17, 41.2%). Other seizure type included atonic seizure, atypical absence, focal seizure, myoclonic-atonic seizure and spasm. Status epilepticus was occurred in 2 patients. Moderate to severe intellectual disability were presented in 13 patients (13/17, 76.5%). Seven patients (7/17, 41.2%) had autistic spectrum disorders. Three patients exhibited microcephalus. Video electroencephalogram were abnormal in 15 patients. All of them had epileptiform discharges during interictal phase, and 8 cases were captured clinical seizures. Two cases has photosensitivity. Brain MRI was normal in all patients. Four cases were diagnosed with myoclonic-atonic epilepsy(MAE), two with febrile seizures plus (FS+), and one with nonspecific developmental epileptic encephalopathy. Seizures have been controlled in 8 (8/17, 47%) patients, 6 of whom have been controlled by valproate and/or levetiracetam. Seizures in 53% (9/17) patients were refractory and required multiple antiepileptic drugs. Three patients used ketogenic diet, two had cognition improvement.

Conclusion: The seizure onset age of patients with CHD2 mutations was in the early childhood. Seizures in most patients were refractory. The majority of patients had developmental delay.


Conference registration is required in order to view papers.